INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 55 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,427,971 | -33.1% | 35,450 | -32.4% | 0.01% | 0.0% |
Q1 2024 | $3,627,602 | -3.4% | 52,422 | 0.0% | 0.01% | -15.4% |
Q4 2023 | $3,754,464 | +37.5% | 52,422 | 0.0% | 0.01% | +30.0% |
Q3 2023 | $2,730,662 | -22.2% | 52,422 | -5.4% | 0.01% | -16.7% |
Q2 2023 | $3,509,891 | +16.9% | 55,431 | 0.0% | 0.01% | +9.1% |
Q1 2023 | $3,001,589 | +2.3% | 55,431 | 0.0% | 0.01% | 0.0% |
Q4 2022 | $2,933,409 | +18.9% | 55,431 | +4.6% | 0.01% | +10.0% |
Q3 2022 | $2,467,000 | -18.5% | 53,010 | 0.0% | 0.01% | -9.1% |
Q2 2022 | $3,026,000 | -6.7% | 53,010 | 0.0% | 0.01% | +10.0% |
Q1 2022 | $3,244,000 | -11.1% | 53,010 | -24.0% | 0.01% | -9.1% |
Q4 2021 | $3,650,000 | +6.8% | 69,728 | -23.9% | 0.01% | 0.0% |
Q3 2021 | $3,418,000 | +25.8% | 91,672 | +37.7% | 0.01% | +22.2% |
Q2 2021 | $2,718,000 | +25.7% | 66,586 | +4.5% | 0.01% | +12.5% |
Q1 2021 | $2,163,000 | -17.2% | 63,743 | -22.4% | 0.01% | -11.1% |
Q4 2020 | $2,612,000 | +21.4% | 82,133 | -2.0% | 0.01% | 0.0% |
Q2 2020 | $2,152,000 | +177.3% | 83,840 | +34.1% | 0.01% | +200.0% |
Q2 2017 | $776,000 | -23.6% | 62,500 | 0.0% | 0.00% | -25.0% |
Q1 2017 | $1,016,000 | +7.7% | 62,500 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $943,000 | -1.0% | 62,500 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $953,000 | -60.7% | 62,500 | 0.0% | 0.00% | -63.6% |
Q2 2016 | $2,426,000 | +39.6% | 62,500 | 0.0% | 0.01% | +37.5% |
Q1 2016 | $1,738,000 | -74.2% | 62,500 | -50.0% | 0.01% | -42.9% |
Q4 2015 | $6,724,000 | +168.6% | 125,000 | +100.0% | 0.01% | +27.3% |
Q3 2015 | $2,503,000 | +74.1% | 62,500 | +38.9% | 0.01% | +83.3% |
Q2 2015 | $1,438,000 | +33.8% | 45,000 | 0.0% | 0.01% | +50.0% |
Q1 2015 | $1,075,000 | +35.4% | 45,000 | 0.0% | 0.00% | +33.3% |
Q4 2014 | $794,000 | +28.7% | 45,000 | 0.0% | 0.00% | +50.0% |
Q3 2014 | $617,000 | -18.7% | 45,000 | 0.0% | 0.00% | -33.3% |
Q2 2014 | $759,000 | – | 45,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |